EMA Authorised: Padcev (Enfortumab vedotin) — Astellas Pharma Europe B.V.

View source ↗

Summary

The European Medicines Agency authorised Padcev (enfortumab vedotin) for urothelial carcinoma and other urologic neoplasms in the European Union.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Urothelial Carcinoma
• Urothelial Neoplasms

Drugs mentioned

• Padcev (enfortumab vedotin)

Snippet

Status: Authorised. Therapeutic area: Carcinoma, Transitional Cell;Urologic Neoplasms. MAH: Astellas Pharma Europe B.V.. Decision date: 17/09/2025